Lidocaine 5% plaster
Lidocaine 5% medicated plaster (Versatis®)* is licensed for the symptomatic relief of neuropathic pain associated with previous herpes zoster (shingles) infection known as post-herpetic neuralgia (PHN) in adults.
The HSE Medicines Management Programme (MMP) has reviewed the evidence available to support the use of lidocaine 5% medicated plaster (Versatis®). (A further review was conducted in 2021 to update clinical evidence relevant to the use of lidocaine medicated plaster.)
Following this review and based on best practice recommendations, the Primary Care Reimbursement Service (PCRS) introduced changes to the reimbursement of lidocaine 5% medicated plaster from 1 September 2017. This process supports appropriate use of this medication while ensuring those with an indication of PHN continue to have access to this treatment.
Prescribing “Tips and Tools” are available to guide appropriate use of lidocaine 5% medicated plaster and offer topical treatment alternatives for both PHN and other types of pain.
Questions and Answers for healthcare professionals are available to explain the reimbursement process for new and existing patients on lidocaine 5% medicated plaster.
Information for patients is also available to explain the changes in relation to lidocaine 5% medicated plaster.
Letter from Medicines Management Programme to Prescribers
*The brand name of this product has now been changed to Versatis 700mg medicated plaster.